Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness

Biomaterials

Volumn 35, Issue 14, 2014, Pages 4310-4318

  Tokuda, Emi Y ^a   Leight, Jennifer L ^a,b   Anseth, Kristi S ^a,b  

^a UCB 450   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

BRAF; Cell viability; ECM (extracellular matrix); Elasticity; Hydrogel; Photopolymerization

Indexed keywords

BRAF; CELL VIABILITY; COMPLIANT SUBSTRATES; ECM (EXTRACELLULAR MATRIX); METASTATIC MELANOMA; MOLECULAR MECHANISM; PHARMACOLOGICAL INHIBITORS; SUBSTRATE STIFFNESS;

CELL CULTURE; CELL DEATH; DERMATOLOGY; DRUG THERAPY; ELASTICITY; ONCOLOGY; PHOTOPOLYMERIZATION; STIFFNESS; STIFFNESS MATRIX; SUBSTRATES; TISSUE;

HYDROGELS;

VEMURAFENIB;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CYTOTOXICITY; ELASTICITY; FOCAL ADHESION; GROWTH CURVE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROGEL; MELANOMA CELL; METASTATIC MELANOMA; PRIORITY JOURNAL; RIGIDITY;

BRAF; CELL VIABILITY; ECM (EXTRACELLULAR MATRIX); ELASTICITY; HYDROGEL; PHOTOPOLYMERIZATION;

APOPTOSIS; BASAL METABOLISM; CELL ADHESION; CELL LINE, TUMOR; CELL SHAPE; CELL-MATRIX JUNCTIONS; CYTOSTATIC AGENTS; ELASTICITY; EXTRACELLULAR MATRIX; HUMANS; HYDROGELS; INDOLES; MELANOMA; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; SULFONAMIDES;

EID: 84896694541     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.063     Document Type: Article

References (49)

1. Breslow A. The surgical treatment of stage I cutaneous melanoma. Cancer Treat Rev 1978, 5:195-198.
2. Bogenrieder T., Herlyn M. Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol 2002, 44:1-15.
3. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
4. Manola J., Atkins M., Ibrahim J., Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000, 18:3782-3793.
5. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105:3041-3046.
6. Lee J.T., Li L., Brafford P.A., van den Eijnden M., Halloran M.B., Sproesser K., et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010, 23:820-827.
7. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
8. Salerno P., De Falco V., Tamburrino A., Nappi T.C., Vecchio G., Schweppe R.E., et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010, 95:450-455.
9. Sala E., Mologni L., Truffa S., Gaetano C., Bollag G.E., Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008, 6:751-759.
10. Davies H., Bignell G., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
11. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
12. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
13. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
14. Cukierman E. Taking cell-matrix adhesions to the third dimension. Science 2001, 294:1708-1712.
15. Debnath J., Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005, 5:675-688.
16. Yamada K., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
17. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
18. Peyton S., Raub C., Keschrumrus V. The use of poly (ethylene glycol) hydrogels to investigate the impact of ECM chemistry and mechanics on smooth muscle cells. Biomaterials 2006, 27:4881-4893.
19. Levental I., Levental K.R., Klein E.A., Assoian R., Miller R.T., Wells R.G., et al. A simple indentation device for measuring micrometer-scale tissue stiffness. J Phys Condens Matter 2010, 22:194120.
20. Bhatia K.S., Yuen E.H., Cho C., Tong C.S., Lee Y.Y., Ahuja A.T. A pilot study evaluating real-time shear wave ultrasound elastography of miscellaneous non-nodal neck masses in a routine head and neck ultrasound clinic. Ultrasound Med Biol 2012, 38:933-942.
21. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
22. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28:4326-4343.
23. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
24. Weigelt B., Lo A.T., Park C.C., Gray J.W., Bissell M.J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010, 122:35-43.
25. Ernfors P. Cellular origin and developmental mechanisms during the formation of skin melanocytes. Exp Cell Res 2010, 316:1397-1407.
26. Lutolf M.P., Raeber G.P., Zisch A.H., Tirelli N., Hubbell J.A. Cell-responsive synthetic hydrogels. Adv Mater 2003, 15:888-892.
27. Hoyle C.E., Bowman C.N. Thiol-ene click chemistry. Angew Chem Int Ed 2010, 49:1540-1573.
28. Fairbanks B.D., Schwartz M.P., Halevi A.E., Nuttelman C.R., Bowman C.N., Anseth K.S. A versatile synthetic extracellular matrix mimic via thiol-norbornene photopolymerization. Adv Mater 2009, 21:5005-5010.
29. Patterson J., Hubbell J.A. Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2. Biomaterials 2010, 31:7836-7845.
30. Anderson S.B., Lin C.-C., Kuntzler D.V., Anseth K.S. The performance of human mesenchymal stem cells encapsulated in cell-degradable polymer-peptide hydrogels. Biomaterials 2011, 32:3564-3574.
31. Gould S.T., Darling N.J., Anseth K.S. Small peptide functionalized thiol-ene hydrogels as culture substrates for understanding valvular interstitial cell activation and de novo tissue deposition. Acta Biomater 2012, 8:3201-3209.
32. Fairbanks B., Schwartz M., Bowman C., Anseth K. Photoinitiated polymerization of PEG-diacrylate with lithium phenyl-2, 4, 6-trimethylbenzoylphosphinate: polymerization rate and cytocompatibility. Biomaterials 2009, 30:6702-6707.
33. Bryant S.J., Anseth K.S. Photopolymerization of hydrogel scaffolds. Scaffolding in tissue engineering 2006, 1-20. CRC Press, Boca Raton, FL. P.X. Ma, J. Ellisseeff (Eds.).
34. Gaggioli C., Robert G., Bertolotto C., Bailet O., Abbe P., Spadafora A., et al. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J Invest Dermatol 2007, 127:400-410.
35. Albelda S.M., Mette S.A., Elder D.E., Stewart R., Danmjanovich L., Herlyn M., et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 1990, 50:6757-6764.
36. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer 2009, 9:108-122.
37. Gambichler T., Moussa G., Sand M., Sand D., Altmeyer P., Hoffmann K. Applications of optical coherence tomography in dermatology. J Dermatol Sci 2005, 40:85-94.
38. Tibbitt M.W., Anseth K.S. Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnol Bioeng 2009, 103:655-663.
39. Kim J.B. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005, 15:365-377.
40. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
41. Szot C.S., Buchanan C.F., Freeman J.W., Rylander M.N. 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials 2011, 32:7905-7912.
42. Chen L., Xiao Z., Meng Y., Zhao Y., Han J., Su G., et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials 2012, 33:1437-1444.
43. Smalley K., Lioni M., Herlyn M. Life isn't flat: taking cancer biology to the next dimension. Vitro Cell Dev Biol Animal 2006, 42:242-247.
44. Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S., et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell Melanoma Res 2010, 23:190-200.
45. Smalley K., Haass N., Brafford P., Lioni M., Flaherty K., Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006, 5:1136-1144.
46. Haass N., Sproesser K., Nguyen T., Contractor R., Medina C., Nathanson K., et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008, 14:230-239.
47. Cushing M., Anseth K. Hydrogel cell cultures. Science 2007, 316:1133-1134.
48. Shao Y., Aplin A.E. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 2010, 70:6670-6681.
49. Boisvert-Adamo K., Aplin A.E. B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene 2006, 25:4848-4856.